Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Targeted drug combination therapy design based on driver genes.

Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I.

Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3.

2.

Regulation of influenza A virus mRNA splicing by CLK1.

Artarini A, Meyer M, Shin YJ, Huber K, Hilz N, Bracher F, Eros D, Orfi L, Keri G, Goedert S, Neuenschwander M, von Kries J, Domovich-Eisenberg Y, Dekel N, Szabadkai I, Lebendiker M, Horváth Z, Danieli T, Livnah O, Moncorgé O, Frise R, Barclay W, Meyer TF, Karlas A.

Antiviral Res. 2019 Aug;168:187-196. doi: 10.1016/j.antiviral.2019.06.003. Epub 2019 Jun 6.

3.

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.

Brauswetter D, Gurbi B, Varga A, Várkondi E, Schwab R, Bánhegyi G, Fábián O, Kéri G, Vályi-Nagy I, Peták I.

PLoS One. 2017 Sep 28;12(9):e0185687. doi: 10.1371/journal.pone.0185687. eCollection 2017.

4.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.

Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML.

Cell Rep. 2017 Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082.

5.

Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.

Ekins S, Godbole AA, Kéri G, Orfi L, Pato J, Bhat RS, Verma R, Bradley EK, Nagaraja V.

Tuberculosis (Edinb). 2017 Mar;103:52-60. doi: 10.1016/j.tube.2017.01.005. Epub 2017 Jan 20.

PMID:
28237034
6.

Effect of pulsed electromagnetic fields on endoplasmic reticulum stress.

Keczan E, Keri G, Banhegyi G, Stiller I.

J Physiol Pharmacol. 2016 Oct;67(5):769-775.

7.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.

Singh V, Dhar N, Pató J, Kolly GS, Korduláková J, Forbak M, Evans JC, Székely R, Rybniker J, Palčeková Z, Zemanová J, Santi I, Signorino-Gelo F, Rodrigues L, Vocat A, Covarrubias AS, Rengifo MG, Johnsson K, Mowbray S, Buechler J, Delorme V, Brodin P, Knott GW, Aínsa JA, Warner DF, Kéri G, Mikušová K, McKinney JD, Cole ST, Mizrahi V, Hartkoorn RC.

Mol Microbiol. 2017 Jan;103(1):13-25. doi: 10.1111/mmi.13535. Epub 2016 Oct 29.

8.

The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.

Singh V, Donini S, Pacitto A, Sala C, Hartkoorn RC, Dhar N, Keri G, Ascher DB, Mondésert G, Vocat A, Lupien A, Sommer R, Vermet H, Lagrange S, Buechler J, Warner DF, McKinney JD, Pato J, Cole ST, Blundell TL, Rizzi M, Mizrahi V.

ACS Infect Dis. 2017 Jan 13;3(1):5-17. doi: 10.1021/acsinfecdis.6b00102. Epub 2016 Sep 8.

9.

Synthesis, characterization and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells.

Murányi J, Gyulavári P, Varga A, Bökönyi G, Tanai H, Vántus T, Pap D, Ludányi K, Mező G, Kéri G.

J Pept Sci. 2016 Aug;22(8):552-60. doi: 10.1002/psc.2904.

PMID:
27443981
10.

Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases.

Booij TH, Klop MJ, Yan K, Szántai-Kis C, Szokol B, Orfi L, van de Water B, Keri G, Price LS.

J Biomol Screen. 2016 Oct;21(9):912-22. doi: 10.1177/1087057116657269. Epub 2016 Jul 7.

11.

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.

Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, Kékesi L, Szabadkai I, Szántai-Kis C, Kéri G, Őrfi L.

Eur J Med Chem. 2016 Jan 27;108:623-643. doi: 10.1016/j.ejmech.2015.12.001. Epub 2015 Dec 12.

PMID:
26724730
12.

Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.

Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):424-428. doi: 10.1016/j.bmcl.2015.11.099. Epub 2015 Nov 28.

PMID:
26704265
13.

Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro.

Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T.

PLoS One. 2015 Dec 16;10(12):e0144792. doi: 10.1371/journal.pone.0144792. eCollection 2015. No abstract available.

14.

Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.

Herrero A, Pinto A, Colón-Bolea P, Casar B, Jones M, Agudo-Ibáñez L, Vidal R, Tenbaum SP, Nuciforo P, Valdizán EM, Horvath Z, Orfi L, Pineda-Lucena A, Bony E, Keri G, Rivas G, Pazos A, Gozalbes R, Palmer HG, Hurlstone A, Crespo P.

Cancer Cell. 2015 Aug 10;28(2):170-82. doi: 10.1016/j.ccell.2015.07.001.

15.

Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Micsik T, Lőrincz A, Mersich T, Baranyai Z, Besznyák I Jr, Dede K, Zaránd A, Jakab F, Szöllösi LK, Kéri G, Schwab R, Peták I.

Diagn Pathol. 2015 Apr 16;10:26. doi: 10.1186/s13000-015-0264-6.

16.

Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro.

Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, Kéri G, Vántus T.

PLoS One. 2015 Apr 14;10(4):e0124234. doi: 10.1371/journal.pone.0124234. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0144792.

17.

Gremlin regulates renal inflammation via the vascular endothelial growth factor receptor 2 pathway.

Lavoz C, Alique M, Rodrigues-Diez R, Pato J, Keri G, Mezzano S, Egido J, Ruiz-Ortega M.

J Pathol. 2015 Aug;236(4):407-20. doi: 10.1002/path.4537. Epub 2015 May 19.

PMID:
25810250
18.

Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.

Sipos A, Pató J, Székely R, Hartkoorn RC, Kékesi L, Őrfi L, Szántai-Kis C, Mikušová K, Svetlíková Z, Korduláková J, Nagaraja V, Godbole AA, Bush N, Collin F, Maxwell A, Cole ST, Kéri G.

Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S200-6. doi: 10.1016/j.tube.2015.02.028. Epub 2015 Feb 28.

PMID:
25801335
19.

Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.

Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, Torka R.

Cancer Biol Ther. 2014;15(11):1571-82. doi: 10.4161/15384047.2014.956634.

20.

[Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction].

Kékesi L, Sipos A, Németh G, Dancsó A, Illyés E, Boros S, Breza N, Nemes Z, Hegymegi-Barakonyi B, Pató J, Greff Z, Kéri G, Őrfi L.

Acta Pharm Hung. 2014;84(3):91-104. Hungarian.

PMID:
25470976
21.

Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.

Rybniker J, Chen JM, Sala C, Hartkoorn RC, Vocat A, Benjak A, Boy-Röttger S, Zhang M, Székely R, Greff Z, Orfi L, Szabadkai I, Pató J, Kéri G, Cole ST.

Cell Host Microbe. 2014 Oct 8;16(4):538-48. doi: 10.1016/j.chom.2014.09.008.

22.

NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.

Barman SA, Chen F, Su Y, Dimitropoulou C, Wang Y, Catravas JD, Han W, Orfi L, Szantai-Kis C, Keri G, Szabadkai I, Barabutis N, Rafikova O, Rafikov R, Black SM, Jonigk D, Giannis A, Asmis R, Stepp DW, Ramesh G, Fulton DJ.

Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1704-15. doi: 10.1161/ATVBAHA.114.303848. Epub 2014 Jun 19.

23.

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.

ACS Med Chem Lett. 2014 Jan 30;5(4):298-303. doi: 10.1021/ml4003309. eCollection 2014 Apr 10.

24.

Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells.

Simon-Szabó L, Kokas M, Mandl J, Kéri G, Csala M.

PLoS One. 2014 Jun 4;9(6):e97868. doi: 10.1371/journal.pone.0097868. eCollection 2014.

25.

Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.

Torka R, Pénzes K, Gusenbauer S, Baumann C, Szabadkai I, Őrfi L, Kéri G, Ullrich A.

Neoplasia. 2014 Apr;16(4):301-18. doi: 10.1016/j.neo.2014.03.009.

26.

Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines.

Mavromatidis V, Varga Z, Waczek F, Őrfi Z, Őrfi L, Kéri G, Mosialos G.

PLoS One. 2014 Apr 23;9(4):e95688. doi: 10.1371/journal.pone.0095688. eCollection 2014.

27.

Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

Németh G, Greff Z, Sipos A, Varga Z, Székely R, Sebestyén M, Jászay Z, Béni S, Nemes Z, Pirat JL, Volle JN, Virieux D, Gyuris Á, Kelemenics K, Ay E, Minarovits J, Szathmary S, Kéri G, Orfi L.

J Med Chem. 2014 May 22;57(10):3939-65. doi: 10.1021/jm401742r. Epub 2014 May 2.

PMID:
24742150
28.

Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.

Baska F, Szabadkai I, Sipos A, Breza N, Szántai-Kis C, Kékesi L, Garamvölgyi R, Nemes Z, Baska F, Neumann L, Torka R, Ullrich A, Kéri G, Orfi L.

Curr Med Chem. 2014 Jun;21(17):1938-55.

PMID:
24606495
29.

[Application of Kohonen Self-Organizing Feature Maps in QSAR of human ADMET and kinase data sets].

Hegymegi-Barakonyi B, Orfi L, Kéri G, Kövesdi I.

Acta Pharm Hung. 2013;83(4):143-8. Hungarian.

PMID:
24575660
30.

[Development and biochemical characterization of EGFR/c-Met dual inhibitors].

Szokol B, Gyulavári P, Baska F, Ibolya K, Greff Z, Szántai KC, Zoltán O, Peták I, Axel U, Vantus T, Kéri G, Orfi L.

Acta Pharm Hung. 2013;83(4):121-33. Hungarian.

PMID:
24575658
31.

Screening for MAPK modulators using an in-cell western assay.

Schnaiter S, Fürst B, Neu J, Wáczek F, Orfi L, Kéri G, Huber LA, Wunderlich W.

Methods Mol Biol. 2014;1120:121-9. doi: 10.1007/978-1-62703-791-4_8.

PMID:
24470022
32.

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.

Győrffy B, Bottai G, Lehmann-Che J, Kéri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de Thè H, André F, Sotiriou C, Hortobagyi GN, Di Leo A, Pusztai L, Santarpia L.

Mol Oncol. 2014 May;8(3):508-19. doi: 10.1016/j.molonc.2013.12.018. Epub 2014 Jan 5.

33.

[Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis].

Baska F, Székely ER, Szántai-Kis C, Bánhegyi P, Hegymegi-Barakonyi B, Németh G, Breza N, Zsákai L, Greff Z, Pató J, Kéri G, Orfi L.

Acta Pharm Hung. 2013;83(3):88-95. Hungarian.

PMID:
24369587
34.

The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells.

Haas DA, Bala K, Büsche G, Weidner-Glunde M, Santag S, Kati S, Gramolelli S, Damas M, Dittrich-Breiholz O, Kracht M, Rückert J, Varga Z, Keri G, Schulz TF.

PLoS Pathog. 2013;9(11):e1003737. doi: 10.1371/journal.ppat.1003737. Epub 2013 Nov 7.

35.

Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.

Kékesi L, Sipos A, Németh G, Pató J, Breza N, Baska F, Őrfi L, Kéri G.

Bioorg Med Chem Lett. 2013 Nov 15;23(22):6152-5. doi: 10.1016/j.bmcl.2013.09.005. Epub 2013 Sep 8.

PMID:
24095095
36.

TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation.

Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M.

J Pathol. 2013 Dec;231(4):480-94. doi: 10.1002/path.4250.

PMID:
24037740
37.

Connective tissue growth factor is a new ligand of epidermal growth factor receptor.

Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, Rodrigues Díez RR, Mas S, Lavoz C, Alique M, Pato J, Keri G, Ortiz A, Egido J, Ruiz-Ortega M.

J Mol Cell Biol. 2013 Oct;5(5):323-35. doi: 10.1093/jmcb/mjt030. Epub 2013 Aug 8.

PMID:
23929714
38.

[Developing FGFR inhibitors as potential anti-cancer agents].

Zsákai L, Németh G, Szántai-Kis C, Greff Z, Horváth Z, Szokol B, Baska F, Boon TC, Orfi L, Kéri G.

Acta Pharm Hung. 2013;83(2):47-56. Hungarian.

PMID:
23926649
39.

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.

Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfî L, Ullrich A, Kéri G, Chua BT.

Curr Med Chem. 2013;20(10):1203-17.

PMID:
23409720
40.

Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.

Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C, Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B.

Biochem Pharmacol. 2012 Aug 1;84(3):260-7. doi: 10.1016/j.bcp.2012.04.010. Epub 2012 Apr 21.

PMID:
22548830
41.

Optimization of important early ADME(T) parameters of NADPH oxidase-4 inhibitor molecules.

Borbély G, Huszár M, Varga A, Futosi K, Mócsai A, Orfi L, Idei M, Mandl J, Kéri G, Vántus T.

Med Chem. 2012 Mar;8(2):174-81.

PMID:
22385185
42.

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.

Dolman ME, Harmsen S, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Storm G, Hennink WE, Kok RJ.

Int J Nanomedicine. 2012;7:417-33. doi: 10.2147/IJN.S26485. Epub 2012 Jan 31.

43.

Characterization of binding mode of imatinib to human α1-acid glycoprotein.

Fitos I, Simon Á, Zsila F, Mády G, Bencsura Á, Varga Z, Orfi L, Kéri G, Visy J.

Int J Biol Macromol. 2012 Apr 1;50(3):788-95. doi: 10.1016/j.ijbiomac.2011.11.023. Epub 2011 Nov 29.

PMID:
22142793
44.

Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue.

Dolman ME, van Dorenmalen KM, Pieters EH, Sparidans RW, Lacombe M, Szokol B, Orfi L, Kéri G, Bovenschen N, Storm G, Hennink WE, Kok RJ.

Macromol Biosci. 2012 Jan;12(1):93-103. doi: 10.1002/mabi.201100277. Epub 2011 Oct 13.

PMID:
21998092
45.

N-Methylated sst2 Selective Somatostatin Cyclic Peptide Analogue as a Potent Candidate for Treating Neurogenic Inflammation.

Chatterjee J, Laufer B, Beck JG, Helyes Z, Pintér E, Szolcsányi J, Horvath A, Mandl J, Reubi JC, Kéri G, Kessler H.

ACS Med Chem Lett. 2011 Apr 4;2(7):509-14. doi: 10.1021/ml200032v. eCollection 2011 Jul 14.

46.

The challenges of integrating molecular imaging into the optimization of cancer therapy.

Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Kéri G, Schaeffter T, Goh V, O'Doherty MJ, Ellis PA, Ng T.

Integr Biol (Camb). 2011 Jun;3(6):603-31. doi: 10.1039/c0ib00131g. Epub 2011 May 4. Review.

PMID:
21541433
47.

Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate.

Harmsen S, Dolman ME, Nemes Z, Lacombe M, Szokol B, Pató J, Kéri G, Orfi L, Storm G, Hennink WE, Kok RJ.

Bioconjug Chem. 2011 Apr 20;22(4):540-5. doi: 10.1021/bc1005637. Epub 2011 Mar 31.

PMID:
21443263
48.

Protein kinase inhibitor as a potential candidate for epilepsy treatment.

Gajda Z, Török R, Horváth Z, Szántai-Kis C, Orfi L, Kéri G, Szente M.

Epilepsia. 2011 Mar;52(3):579-88. doi: 10.1111/j.1528-1167.2011.02979.x. Epub 2011 Mar 3.

49.

How Förster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology.

Fruhwirth GO, Fernandes LP, Weitsman G, Patel G, Kelleher M, Lawler K, Brock A, Poland SP, Matthews DR, Kéri G, Barber PR, Vojnovic B, Ameer-Beg SM, Coolen AC, Fraternali F, Ng T.

Chemphyschem. 2011 Feb 25;12(3):442-61. doi: 10.1002/cphc.201000866. Epub 2011 Feb 15. Review.

PMID:
21328516
50.

[Synthesis of 4-Chloro-6-(substituted-phenyl)-pyrimidines].

Németh G, Varga Z, Greff Z, Kéri G, Orfi L.

Acta Pharm Hung. 2010;80(3):101-8. Hungarian.

PMID:
21222319

Supplemental Content

Support Center